Acne Vulgaris Therapeutics Market Size in the 7MM was ~USD 4,256 Million in 2023 and is projected to increase by 2034 | DelveInsight

DelveInsight's "Acne Vulgaris Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Acne Vulgaris, historical and forecasted epidemiology as well as the Acne Vulgaris therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock key insights into the Acne Vulgaris Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Acne Vulgaris Market Size [https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Acne Vulgaris Market Report

* In Dec 2024:- Dermata Therapeutics, Inc. received FDA approval for the proprietary name Xyngari (formerly DMT310) for its Phase III clinical drug candidate in acne. The approval is pending sthe uccessful submission and acceptance of an NDA.
* In 2023, an estimated ~140,217 thousand Acne Vulgaris Prevalent Cases occurred across the 7MM, with approximately 69,500 thousand cases attributed to the US alone. These numbers are expected to increase steadily throughout the forecast period.
* The categorization based on gender, showed that Acne Vulgaris diagnosed prevalent cases in females were higher than in males in the 7MM. The female-diagnosed prevalent cases accounted for 63% of the total cases in the 7MM.
* The Acne Vulgaris Prevalent Cases were sub-segmented further based on the severity of the acne as mild, moderate, and severe. In 2023, the highest diagnosed prevalent cases of acne vulgaris were reported as moderate (45%), whereas there were least cases in the severe (10%) segment in the 7MM.
* The leading Acne Vulgaris Companies such as Galderma Labs, Ortho Dermatologics, Bausch Health, Timber Pharmaceuticals, BioPharmX, Botanix Pharmaceuticals, Kintor Pharma , and others.
* Promising Acne Vulgaris Therapies such as B244, SB204, DMT310, BTX 1503 , and others.

Stay ahead in the competitive landscape of the Acne Vulgaris Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Acne Vulgaris Treatment Market Size [https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acne Vulgaris Epidemiology Segmentation in the 7MM

* Acne Vulgaris Prevalent Cases
* Acne Vulgaris Diagnosed Prevalent Cases
* Acne Vulgaris Severity-specific Diagnosed Prevalent Cases
* Acne Vulgaris Gender-specific Diagnosed Prevalent Cases
* Acne Vulgaris Age-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Acne Vulgaris epidemiology trends @ Acne Vulgaris Prevalence [https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acne Vulgaris Marketed Drugs

* AKLIEF (Trifarotene)/ CD-5789: Galderma S.A.

Trifarotene, a first-in-class fourth-generation topical retinoid, has been approved by the FDA for the treatment of acne vulgaris in patients aged 9 years and older. This novel retinoid selectively targets retinoic acid receptor gamma (RAR?), the most common RAR found in the skin, making it a more targeted and skin-specific treatment compared to earlier-generation retinoids. Trifarotene is effective in reducing inflammatory lesions on the face and trunk, with significant improvements observed as early as 2 weeks on the face and 4 weeks on the back, shoulders, and chest. The cream is well tolerated, with common adverse reactions including application-site irritation, pruritus, and sunburn.

* AMZEEQ (minocycline): Journey Medical Corporation/Vyne Therapeutics Inc.

In 2019, the FDA approved AMZEEQ, a foam formulation of the tetracycline antibiotic minocycline, for treating severe acne in adults and children aged 9 years and older. AMZEEQ is specifically indicated for treating pimples and red bumps (non-nodular inflammatory lesions) linked to moderate to severe acne. This new formulation utilizes Foamix's proprietary Molecule Stabilizing Technology (MST) platform to deliver minocycline in a foam form, offering a more targeted and effective treatment option. Furthermore, minocycline is also approved by the FDA for treating rosacea in adult patients, expanding its therapeutic applications in dermatology.

* ARAZLO (tazarotene): Bausch Health Companies Inc. / Ortho Dermatologics

ARAZLO, a topical cream containing tazarotene as the active ingredient, is a treatment option for acne vulgaris in patients aged 9 years and older. The cream combines tazarotene with three moisturizers: sebacic acid, light mineral oil, and sorbitol, allowing it to be highly effective against acne while minimizing skin irritation. Additionally, ARAZLO lotion employs patented polymeric emulsion technology, which enhances skin absorption and reduces irritation, making it a comprehensive treatment option for acne patients.

Acne Vulgaris Emerging Drugs

* SB204: Pelthos Therapeutics

SB204, an investigational topical nitric oxide-releasing drug developed by Pelthos Therapeutics, has shown promising efficacy in treating acne vulgaris. This topical monotherapy is designed to address the multi-factorial nature of acne, which involves four key pathophysiological factors: inflammation, bacterial colonization, and other factors. SB204 utilizes the same active pharmaceutical ingredient as berdazimer gel 10.3% and is formulated to provide anti-inflammatory and anti-bacterial activity, making it a potential treatment option for acne patients.

* B244: AOBiome LLC

B244 is a proprietary topical formulation that incorporates a single strain of beneficial AOB, Nitrosomonas eutropha, developed by AOBiome. This patented formulation is designed to restore the skin microbiome by repopulating it with AOBs that are naturally present in the body but often stripped away by most soaps. Once applied to the skin, B244 converts ammonia into nitrite, which exhibits antibacterial properties, and nitric oxide, a signaling molecule that regulates inflammation and vasodilation. Furthermore, this strain of AOB has been shown to reduce inflammatory and pruritic cytokines, such as IL-4, IL-5, IL-13, and IL-31, which are characteristic of atopic responses, thereby providing a comprehensive treatment option for skin conditions.

* DMT310: Dermata Therapeutics

DMT310, developed by Dermata Therapeutics from Spongilla platform technology, is under clinical investigation for the treatment of acne vulagris. The novel product candidate comes from a naturally occurring source of Spongilla lacustris, which has several active ingredients that act by targeting interleukin 17A and 17F. In November 2023, Dermata Therapeutics received an FDA response to its DMT310 Phase II study concentrating on the treatment of medical and cosmetic skin conditions. Currently the drug is being evaluated in Phase III of clinical development for the treatment of acne vulgaris.

Discover the future of Acne Vulgaris Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Acne Vulgaris Market Drivers and Barriers [https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acne Vulgaris Market Outlook

Effective management of acne requires a comprehensive approach that addresses the underlying factors and incorporates lifestyle modifications, topical treatments, and systemic therapies as needed. The current Acne Vulgaris treatment market for acne vulgaris is driven by the increasing prevalence of acne, rising awareness of skincare, and the need for alternative treatment options. Key developments include a diverse array of topical and systemic therapies, each targeting specific aspects of the complex pathogenesis of this common skin disorder. Topical treatments such as salicylic acid and azelaic acid are used to improve skin moisture, reduce inflammation, and eliminate comedones. Systemic therapies, including oral antibiotics like tetracycline and doxycycline, oral retinoids like isotretinoin, and hormonal agents like spironolactone, are utilized for severe cases.

Scope of the Acne Vulgaris Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Acne Vulgaris Companies- Galderma Labs, Ortho Dermatologics, Bausch Health, Timber Pharmaceuticals, BioPharmX, Botanix Pharmaceuticals, Kintor Pharma, and others.
* Acne Vulgaris Therapies- B244, SB204, DMT310, BTX 1503, and others.
* Acne Vulgaris Therapeutic Assessment: Acne Vulgaris Current Marketed and Acne Vulgaris Emerging Therapies
* Acne Vulgaris Market Dynamics: Acne Vulgaris market drivers and Acne Vulgaris market barriers
* Acne Vulgaris Unmet Needs, KOL's views, Analyst's views, Acne Vulgaris Market Access and Reimbursement

Explore the dynamics of the Acne Vulgaris Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Acne Vulgaris Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1 Key Insights

2 Report Introduction

3 Acne Vulgaris Epidemiology Overview at a Glance

4 Epidemiology Forecast Methodology

5 Executive Summary

6 Key Events

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 KOL Views

11 Appendix

12 DelveInsight Capabilities

13 Disclaimer

14 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acne-vulgaris-therapeutics-market-size-in-the-7mm-was-usd-4256-million-in-2023-and-is-projected-to-increase-by-2034-delveinsight]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/lactose-intolerance-market



This release was published on openPR.